BTX - Brooklyn Therapeutics sees mRNA license as key to future but shares down 6%

Brooklyn Therapeutics' (BTX) exclusive license for mRNA gene editing and cell therapies technology, combined with a desire to form additional partnership, will help drive value and grow the company in the future, according to CEO Howard Federoff.Speaking during an after-the-bell conference call today, Federoff said that the license, acquired last month from Factor Bioscience and Novellus Therapeutics, will allow the company to diversify from just focusing on immunotherapies.He noted that gene editing can be used to modify stem cells so they might be able to kill cancer in situ.Federoff added that the intellectual property behind the mRNA license extends to 2039.In the pipeline, Federoff said that top-line phase 2b data readout of the company's sole clinical candidate, IRX-2, for squamous cell cancer of the head and neck, is on track for 1H 2022.The company's recently completed $20M equity line has brought cash on hand to $23M, enough to keep operations going

For further details see:

Brooklyn Therapeutics sees mRNA license as key to future, but shares down 6%